James B. Hawkins’s recent Form 4 activity reveals a clear asymmetry: he has been a consistent open-market buyer of AudioEye (AEYE) while simultaneously trimming his position in iRadimed (IRMD), with his holdings in OSI Systems (OSIS) driven largely by automatic compensation mechanics. Over the full filing history, Hawkins has executed 46 transactions across three companies, with total open-market sales ($2.22 million) outpacing open-market purchases ($775,318), but the recent pattern shows a decisive shift toward accumulation in AEYE.
The buying bias is concentrated and recent. Between November 11, 2025, and March 12, 2026, Hawkins made nine open-market purchases of AEYE totaling roughly $460,000, with individual trades ranging from $22,100 to $100,600. The largest single buy came on November 11, 2025, at $100,600, followed by $71,419.80 two days later, and a cluster of smaller purchases in the $22,000–$23,000 range through late November. The buying resumed in March 2026 with three consecutive purchases—$82,713.40, $74,999.60, and $62,031.20—on March 10, 11, and 12. These are the only “P” codes in the recent window, marking them as discretionary conviction buys.
In contrast, Hawkins’s IRMD activity shows a clear selling bias. On November 20, 2025, he executed four separate open-market sales totaling $167,890.52, followed by a larger $289,837.50 sale on December 9, 2025. Those sales were preceded by option exercises (coded “M”) on December 7 and December 11, suggesting the shares sold were sourced from exercised options. His OSIS transactions are entirely mechanical—grants (coded “A”) and tax-withholding forfeitures (coded “F”)—with no open-market buying or selling. The most recent OSIS grant on July 20, 2026, was valued at $200,184.60, but it represents compensation, not a directional bet. Overall, the recent data points to a director or officer who is accumulating AEYE shares in the open market while monetizing IRMD holdings, with OSIS activity reflecting routine equity compensation.
AI-assisted summary